Feature | March 27, 2012

Antiplatelet Drug Reduces Damage to Heart Muscle in Heart Attack Patients

Results of the INFUSE-AMI trial presented at ACC; clot aspiration not effective

Atrium Medicals ClearPath infusion catheter.

Medtronics Export aspiration catheter.

Data from the INFUSE-AMI trial, showing little difference in patients treated with clot aspiration, versus no aspiration.

Data from the INFUSE-AMI trial, showing little difference in patients treated with clot aspiration, versus no aspiration.

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most severe type of heart attack. Results of the INFUSE-AMI trial were presented at the American College of Cardiology’s 61st Annual Scientific Session and published simultaneously in the March 25 online issue of the Journal of the American Medical Association. Researchers also found that clot aspiration did not significantly reduce the damage to the heart muscle.

“Results from the INFUSE-AMI trial suggest that in patients with large heart attacks reaching the hospital early, the extent of heart damage can be reduced with a bolus of intracoronary abciximab delivered directly to the infarct lesion,” said lead investigator, Gregg W. Stone, M.D. He is professor of medicine at Columbia University College of Physicians and Surgeons, and director of research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital. Stone also serves as co-director of the medical research and education division at the Cardiovascular Research Foundation.

The primary efficacy endpoint was heart attack size at 30 days, as measured by cardiac magnetic resonance imaging (MRI) for 382 of 439 surviving patients (87.1%). Abciximab was delivered locally to the site of the blocked artery using a novel catheter, the ClearWay Rx (Atrium Medical). Heart attack size was measured by calculating infarct size as a percentage of total heart muscle tissue. Patients in the two abciximab arms had significantly smaller heart attacks than patients in the two no-abciximab arms (median 15.1 vs. 17.9%).

In contrast, aspiration thrombectomy did not significantly decrease heart attack size (17%) compared with no aspiration (17.3%). The aspiration plus abciximab group showed the lowest median heart attack size of 14.7%, compared with 17.6% for the other three groups combined. There were no significant differences among the four groups for any major measures of safety or efficacy at 30 days. Patients will be assessed again at six months and one year.

“A large randomized clinical trial of intracoronary abciximab delivered to the site of the infarct lesion through the ClearWay Rx catheter is needed to determine whether this therapy results in improved clinical outcomes without excessive bleeding,” Stone said.

“Additionally, in this trial, aspiration did not reduce infarct size. However, the final word about aspiration in STEMI will be spoken by the results from two large ongoing randomized trials of aspiration powered for mortality,” Stone added. These trials include TOTAL and TASTE.

The INFUSE-AMI trial used a 2 x 2 factorial design, isolating the impact of each intervention to maximize the chance of identifying any reduction in heart attack size. The trial, conducted at 37 sites in six countries, screened 6,318 patients and enrolled only 452 (7.2 percent) with large heart attacks presenting early, during the time when reduction in the size of the heart attack is still possible. The trial was a single-blind study in which the operator knew the randomization assignments.

All study subjects were treated with the anticoagulant bivalirudin, and randomly assigned to one of four arms: (1) aspiration plus abciximab, (2) aspiration without abciximab, (3) no aspiration plus abciximab, and (4) no aspiration or abciximab (control). In the two abciximab arms, a balloon catheter (ClearWay Rx) delivered the drug right to the site of the lesion, which invariably has thrombus present. Aspiration was accomplished through an Export (Medtronic) catheter. All patients who had angioplasty were also treated with bivalirudin, an anticoagulant that keeps bleeding and mortality low.

The INFUSE-AMI trial was funded by Atrium Medical, manufacturer of the ClearWay RX catheter, and Medtronic Inc., manufacturer of the Export catheter, and conducted by the Cardiovascular Research Foundation. Stone reported consulting fees from Abbott Vascular, Boston Scientific, Medtronic, Atrium, The Medicines Company, Merck, Daiichi Sankyo and Eli Lilly.

This study was simultaneously published in the Journal of the American Medical Association and released online at the time of presentation.

For more information: www.crf.org

Related Content

CSI recall for saline pump on its atherectomy system
News | Atherectomy Devices| April 19, 2017
Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...
Louisiana Medical Center Installs First U.S. Toshiba Medical Infinix-i Sky +
News | Angiography| April 18, 2017
April 18, 2017 — Patients at Terrebonne General Medical Center (TGMC) in Houma, La., now have access to safe, high-qu
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
University of California Study Searches for Consistent CT Dose Best Practices
News | Radiation Dose Management| April 17, 2017
A new study led by UC San Francisco has found that radiation doses can be safely and effectively reduced – and more...
Study Finds Significant Variability in Doctors Angioplasty Death Rates
News | Cath Lab| April 17, 2017
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as...
Grey Hair Linked With Increased Heart Disease Risk in Men
News | Cardiac Diagnostics| April 14, 2017
Grey hair has been linked with an increased risk of heart disease in men, in research presented recently at EuroPrevent...
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Overlay Init